Betashares Asia Technology Tigers ETF vs Betashares Global Healthcare Currency Hedged ETF
Overlap is calculated from each fund's full published holdings list. Where there are no shared listed holdings it is shown as not reliably estimable.
ASIA and DRUG are both Thematic ETFs. ASIA tracks the Solactive Asia ex-Japan Technology and Internet Tigers Index and DRUG tracks the MarketGrader Developed World Healthcare Index. DRUG has the lower management fee (0.45% vs 0.67% p.a.). Holdings overlap is approximately 0% (full holdings data).
Betashares Asia Technology Tigers ETF
BetaShares
Betashares Global Healthcare Currency Hedged ETF
BetaShares
Comparison scores reflect how each ETF compares to the other on these specific dimensions only. They are not absolute ratings or recommendations.
Key differences at a glance
ASIA and DRUG suit different goals rather than one being "better" than the other. The clearest differences:
Category scores compare these two ETFs only and are not absolute ratings.
DRUG has the lower management fee - the one objective "cheaper" axis.
ASIA is the larger fund. Larger is not inherently better, but greater scale can support tighter spreads and lower closure risk.
DRUG spreads exposure across more holdings (ASIA 50, DRUG 59); the other is more concentrated. Neither is inherently better - it depends on whether you want breadth or a focused tilt.
ASIA distributes approximately 1.9% and DRUG approximately 4%; DRUG carries the higher estimated distribution yield. A higher yield may suit an income focus; a lower one may suit a growth or tax-efficiency focus. Yields are estimates and are not guaranteed; past performance is not a reliable indicator of future returns.
Green highlights the factually lower fee or higher scale/income figure. Performance is never highlighted. Data from issuer disclosures, reviewed quarterly.
Yield figures are estimates based on recent distributions and may vary. Past distributions are not a reliable indicator of future distributions.
Past performance is not a reliable indicator of future returns.
Top shared holdings ranked by overlap contribution, the smaller of each company's weight in the two funds. Basis: full holdings data.
Top 10 listed holdings for each fund, from issuer disclosures.
ASIA top holdings
DRUG top holdings
Based on each fund's most recently published sector and geographic weightings; figures are approximate. Full breakdowns are shown below.
ASIA sectors
DRUG sectors
ASIA geography
DRUG geography
ASIA and DRUG can each make sense depending on your objectives, horizon and existing portfolio. The key differences are near the top of this page, and the full side-by-side data is below.
ASIA and DRUG have approximately 0% holdings overlap, based on each fund's full published holdings list. This is considered low overlap.
DRUG has the lower management fee. ASIA charges 0.67% per year ($67 per year on a $10,000 investment) and DRUG charges 0.45% per year ($45 per year on a $10,000 investment). The difference is $22 per year per $10,000 invested.
ASIA (Betashares Asia Technology Tigers ETF) manages approximately $1.3B and DRUG (Betashares Global Healthcare Currency Hedged ETF) manages approximately $158M. Fund size can affect liquidity and bid-ask spreads but does not by itself change the management fee.
You can hold both, but with approximately 0% estimated holdings overlap the two funds hold mostly different companies, so they can be more complementary. Whether that suits you depends on your own objectives.
There is no universally right choice. It depends on your goals, time horizon and existing holdings. ASIA charges 0.67% and DRUG charges 0.45%, so DRUG has the lower management fee, and they have approximately 0% estimated holdings overlap. Compare their fees, holdings and sectors above and consider each fund's Product Disclosure Statement and Target Market Determination.
General information only. This comparison and the ETFLens tools on this page provide general information about two exchange-traded funds and do not take into account your personal objectives, financial situation or needs. It is not personal financial product or investment advice. ETFLens does not hold an Australian Financial Services Licence (AFSL). Holdings overlap is calculated from each fund's published holdings (full lists where the issuer publishes one, listed top holdings otherwise), and fee data is sourced from fund manager PDS documents and updated quarterly. Past performance is not a reliable indicator of future returns. Consider each fund's Product Disclosure Statement (PDS) and Target Market Determination (TMD), and seek advice from a registered tax agent or licensed financial adviser, before making investment decisions.
Check your portfolio overlap
See how these ETFs interact with your other holdings.
Open overlap checker →Build your portfolio
ProModel a portfolio with these ETFs and see projected fees and income.
Build a portfolio →View full ETF profiles
Holdings, fees, sectors and distributions for each fund.
ASIA full profile →DRUG full profile →Compare another pair
Enter any two ASX ETF tickers to see their side-by-side comparison.
Compare other ETFs →